Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis. Promedior is advancing PRM-151, a recombinant form of an endogenous human protein that offers the potential to prevent and potentially reverse fibrosis. The Phase 2 clinical study of PRM-151 in patients with myelofibrosis, which is expected to complete in 2014, expands Promedior’s clinical focus beyond IPF to myelofibrosis, another serious, life-limiting orphan disease with significant unmet medical need.
“Advancing the clinical development of PRM-151, our lead product candidate, into clinical studies in myelofibrosis patients is a significant milestone for Promedior,” said Elizabeth G. Trehu, MD, FACP, Promedior’s Chief Medical Officer. “We are optimistic that data from this study, combined with the encouraging data in IPF, will demonstrate that PRM-151’s novel mechanism of action is applicable to a wide range of fibrotic diseases.”
Read the entire article at: